Conference ”Breast cancer heterogeneity and resistance to endocrine therapy”le 24/09 de 14h30 à 16h
Maria Vivanco from Bilbao (CIC BioGune) will give the next TRAIL conference at the Institut Bergonié on Sept. 24th (starting time 2:30 p.m.)
”Breast cancer heterogeneity and resistance to endocrine therapy”
Breast cancer is a heterogeneous disease, which in part arises from the existence of cells with stem-like properties (cancer stem/progenitor cells, CSCs). The identification and characterisation of CSCs in breast cancer has opened new possibilities for anti-cancer therapies. CSCs are implicated in tumour initiation and resistance to current treatments, including endocrine therapy. Increase of CSC content during development of resistance to tamoxifen in breast cancer is driven by multiple signals, including Sox2-dependent activation of Wnt signalling. We have found that Sox2 overexpression leads to increased expression of Sox9, a transcription factor expressed in stem/progenitor cells in multiple tissues and in most solid tumours. Sox9 marks luminal progenitor cells and is required for the maintenance of the mammary stem/progenitor cell pool in the human breast epithelium. Sox9 is overexpressed in breast
tumours compared to their normal counterparts and affects the self-renewal capacity of progenitor cells in different breast cancer cell types. These findings highlight the relevance of Sox family transcription factors as potential therapeutic targets in breast cancer.